Loading...
•
Sep 30, 2022
Zentalis Q3 2022 Earnings Report
Zentalis reported third quarter 2022 financial results and provided operational updates.
Key Takeaways
Zentalis Pharmaceuticals reported a cash balance of $422 million as of September 30, 2022, with a projected cash runway into 2025. The company is advancing its clinical strategy for ZN-c3, including dose optimization and expansion into Cyclin E driven high-grade serous ovarian cancer. Collaborations with Pfizer and GSK are ongoing to explore ZN-c3 in combination therapies.
Advanced clinical strategy for ZN-c3 with three-pronged development plan.
Identified Cyclin E driven high-grade serous ovarian cancer patients as initial expansion population for ZN-c3 biomarker monotherapy trial.
Announced first ZN-c3 clinical development collaboration with Pfizer BRAF-mutant mCRC; Expanded ZN-c3 clinical development collaboration with GSK in PARP resistant ovarian cancer.
Declared BCL-xL protein degrader candidate and initiated IND-enabling studies.
Forward Guidance
Zentalis believes that its existing cash, cash equivalents and marketable securities as of September 30, 2022 will be sufficient to fund its operating expenses and capital expenditure requirements into the first quarter of 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...